Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Dose-escalation and Extension, Phase I Clinical Study on Evaluating Safety, Tolerability and Pharmacodynamics of Intravenous Administration of IDOV-SAFE in Patients With Advanced Malignant Solid Tumors Who Have Failed in Standard Treatment.

NCT06380309 is registered in ClinicalTrials.gov with Peking University as lead sponsor.

NCT NCT06380309
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06380309 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Dose-escalation and Extension, Phase I Clinical Study on Evaluating Safety, Tolerability and Pharmacodynamics of Intravenous Administration of IDOV-SAFE in Patients With Advanced Malignant Solid Tumors Who Have Failed in Standard Treatment.
Lead sponsor
Peking University
Phase
Phase 1
Overall status
Recruiting
Start date
May 6, 2024
Completion date
October 30, 2027
Enrollment
89 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignant solid tumor of digestive system